These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 26974314

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J.
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [Abstract] [Full Text] [Related]

  • 5. Dual phase qualitative and quantitative 99mTc-MIBI scintimammography for predicting response to neoadjuvant chemotherapy in breast cancer.
    Zaman MU, Nasir Z, Raza T, Hashmi H, Hashmi A, Fatima N.
    J Coll Physicians Surg Pak; 2009 Mar; 19(3):173-8. PubMed ID: 19268018
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Sciuto R, Pasqualoni R, Bergomi S, Petrilli G, Vici P, Belli F, Botti C, Mottolese M, Maini CL.
    J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
    [Abstract] [Full Text] [Related]

  • 13. Contribution of 99mTc-anti-carcinoembryonic antigen antibody and 99mTc-sestamibi scintimammography in the evaluation of high risk palpable breast lesions.
    Sanidas EE, Koukouraki S, Velidaki A, Manios A, Stathopoulos E, De Bree E, Kafousi M, Kodogiannis E, Karkavitsas N, Tsiftsis DD.
    Nucl Med Commun; 2003 Mar; 24(3):291-6. PubMed ID: 12612470
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Can scintimammography with (99m)Tc-MIBI identify multifocal and multicentric primary breast cancer?
    Cwikla JB, Buscombe JR, Holloway B, Parbhoo SP, Davidson T, McDermott N, Hilson AJ.
    Nucl Med Commun; 2001 Dec; 22(12):1287-93. PubMed ID: 11711898
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography.
    Gommans GM, van der Zant FM, van Dongen A, Boer RO, Teule GJ, de Waard JW.
    Eur J Surg Oncol; 2007 Feb; 33(1):23-7. PubMed ID: 17126524
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The comparison of dual phase Tc-99m MIBI and tc-99m MDP scintimammography in the evaluation of breast masses: preliminary report.
    Arslan N, Ozturk E, Ilgan S, Narin Y, Dundar S, Tufan T, Pekcan M, Bayhan H.
    Ann Nucl Med; 2000 Feb; 14(1):39-46. PubMed ID: 10770579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.